# **Enterprise Multi-Agent Architecture for Drug Repurposing Automation**

## **1. Agent Roles & Specialization**

### **Core Research Agents**
- **Literature Extraction Agent**
  - *Tools*: PubMed/Medline API, Semantic Scholar, BioBERT/PubMedBERT models
  - *Capabilities*: Entity recognition (drugs, targets, diseases), relationship extraction, confidence scoring
  - *Output*: Structured evidence with citations, PMIDs, publication dates

- **Multi-Omics Integration Agent**
  - *Tools*: LINCS, GEO, TCGA data connectors, pathway analysis engines
  - *Capabilities*: Gene expression correlation, pathway enrichment, network pharmacology
  - *Output*: Mechanistic hypotheses with pathway perturbation scores

- **Clinical Trial Synthesis Agent**
  - *Tools*: ClinicalTrials.gov API, EU CTR parser, trial outcome normalizer
  - *Capabilities*: Cross-trial meta-analysis, endpoint harmonization, population matching
  - *Output*: Efficacy signals with GRADE-like quality assessments

### **Evaluation & Validation Agents**
- **PK/PD Evaluator Agent**
  - *Tools*: GastroPlus/Simcyp simulators, physiologically-based PK models
  - *Capabilities*: Dose projection, tissue penetration prediction, DDI assessment
  - *Output*: Feasibility scores with uncertainty quantification

- **Safety & Toxicity Agent**
  - *Tools*: FAERS/EudraVigilance miners, Tox21/ToxCast predictors
  - *Capabilities*: Adverse event signal detection, therapeutic index calculation
  - *Output*: Risk-benefit profiles with contraindication flags

- **Biomarker & Companion Diagnostic Agent**
  - *Tools*: Biomarker database connectors, assay feasibility analyzers
  - *Output*: Patient stratification strategies and diagnostic development paths

### **Business & Compliance Agents**
- **Patent/IP Landscape Agent**
  - *Tools*: USPTO/EPO/Lens.org API, claim analyzer, freedom-to-operate assessor
  - *Capabilities*: Patent expiration mapping, competitive intelligence
  - *Output*: IP risk assessment and protection strategy

- **Regulatory Strategy Agent**
  - *Tools*: FDA guidance NLP analyzer, precedent case database
  - *Capabilities*: Regulatory pathway prediction, dossier requirement mapping
  - *Output*: Development pathway with regulatory milestones

- **Commercial Viability Agent**
  - *Tools*: Market access analyzers, pricing modelers, epidemiological databases
  - *Output*: Market size estimates and ROI projections

## **2. Data Flow Architecture**

```
[Data Sources Layer]
├── External APIs (PubMed, ClinicalTrials.gov, FAERS, Patent DBs)
├── Internal Data Lakes (HTS, omics, clinical databases)
├── Commercial Databases (Cortellis, Citeline)

[Ingestion & Harmonization Layer]
├── MedDRA/WHO-DD term normalization
├── Cross-database entity resolution
├── Temporal alignment of evidence

[Agent Orchestration Layer - CrewAI Implementation]
├── Task Router: Directs queries to appropriate agent sequences
├── Workflow Manager: Parallel/sequential execution control
├── Evidence Integrator: Conflict resolution and consensus building

[Knowledge Synthesis Layer]
├── Evidence Graph Builder: Creates connected knowledge network
├── Confidence Scorer: Bayesian belief network for evidence weighting
├── Hypothesis Ranker: Multi-criteria decision analysis engine

[Output & Reporting Layer]
├── Structured Report Generator (CDISC-compatible)
├── Regulatory Document Assembler
├── Dashboard & Alert System
```

## **3. Validation Logic Framework**

### **Multi-Tier Validation**
- **Level 1**: Source credibility scoring (journal impact, trial phase, sample size)
- **Level 2**: Cross-validation across data types (literature ↔ trials ↔ omics)
- **Level 3**: Mechanistic plausibility assessment (biological pathway coherence)
- **Level 4**: External validation against hold-out datasets
- **Level 5**: Expert-in-the-loop confirmation for high-impact findings

### **Statistical Validation**
```python
# Pseudo-validation pipeline
validation_pipeline = {
    "bias_detection": ["publication_bias", "trial_design_bias"],
    "sensitivity_analysis": ["evidence_removal", "parameter_perturbation"],
    "reproducibility": ["cross_database_validation", "temporal_validation"],
    "calibration": ["prediction_interval_coverage", "Brier_score"]
}
```

## **4. Governance Layer (21 CFR Part 11 Compliant)**

### **Audit Trail Implementation**
```
AuditRecord {
    timestamp: ISO8601_with_timezone,
    user_id: LDAP_username,
    agent_id: versioned_agent_identifier,
    action: CRUD_operation,
    input_hash: SHA-256,
    output_hash: SHA-256,
    rationale: decision_log,
    digital_signature: RSA-2048
}
```

### **Access Control Matrix**
- **Role-based access** (Scientist, QA, Auditor, Admin)
- **Data sensitivity tiers** (Public, Internal, Restricted, Confidential)
- **Time-bound access** for temporary permissions
- **Four-eyes principle** for critical decisions

### **Model Validation Framework**
- **Pre-deployment**: IQ/OQ/PQ documentation
- **Continuous monitoring**: Drift detection (data drift, concept drift)
- **Periodic revalidation**: Quarterly performance reassessment
- **Change control**: Version-controlled model registry

## **5. Data Infrastructure & Indexing Strategy**

### **Vector Database: Weaviate Enterprise**
- **Justification**: Native multi-tenancy, hybrid search (vector + keyword), built-in module system
- **Indexing**: HNSW with product quantization for billion-scale similarity search
- **Schema**: Domain-specific classes (Compound, Target, Disease, Pathway) with cross-references

### **Graph Database: Neo4j AuraDB Enterprise**
- **Justification**: Cypher query language, native graph algorithms, ACID compliance
- **Schema**:
```cypher
(Compound)-[HAS_MOA]->(Target)
(Target)-[INVOLVED_IN]->(Pathway)
(Pathway)-[IMPLICATED_IN]->(Disease)
(ClinicalTrial)-[EVALUATES]->(Compound:Disease)
```

### **Hybrid Search Strategy**
1. **Primary retrieval**: Vector similarity on embeddings (768d BioBERT)
2. **Secondary filtering**: Graph traversal for relationship constraints
3. **Tertiary ranking**: Learning-to-rank with multi-feature ensemble
4. **Cache layer**: Redis for frequent query patterns

## **6. Provenance & Reproducibility Framework**

### **Provenance Tracking**
- **Data lineage**: Full trace from raw source to final recommendation
- **Version pinning**: Docker containers, model versions, dataset snapshots
- **Environment capture**: Conda/Pipenv lock files, system dependencies

### **Reproducibility Guarantees**
```yaml
reproducibility_stack:
  containerization: "Singularity/Apptainer for HPC compatibility"
  workflow_orchestration: "Nextflow with Conda/Container integration"
  experiment_tracking: "MLflow + DVC for data/model versioning"
  compute_specification: "SPDX Software Bill of Materials"
```

### **Regulatory Documentation Package**
- **Technical File**: System architecture, validation protocols
- **Risk Management File**: ISO 14971 compliant risk analysis
- **Usability File**: Human factors engineering documentation
- **Clinical Evaluation Report**: For regulatory submissions

## **7. Performance Benchmarks & SLAs**

### **Enterprise Deployment Metrics**
```
Query Performance:
- Simple query (single agent): < 30 seconds
- Complex multi-agent hypothesis: < 2 hours
- Batch processing (1000 compounds): < 24 hours

System Reliability:
- Uptime: 99.95% (excluding scheduled maintenance)
- Data freshness: Clinical trials < 24h, Literature < 72h
- Recovery Time Objective (RTO): < 4 hours
- Recovery Point Objective (RPO): < 15 minutes

Quality Metrics:
- Precision@10 for compound retrieval: > 0.85
- Recall of known repurposing cases: > 0.90
- False positive rate: < 0.05
- Expert validation concordance: > 0.80 Cohen's Kappa

Scalability:
- Concurrent users: Support 200+ researchers
- Data volume: Petabyte-scale evidence storage
- Agent scaling: Kubernetes horizontal pod autoscaling
```

### **Validation Benchmarks**
- **Cross-validation**: Leave-one-database-out testing
- **Prospective validation**: Monthly blind predictions vs. new publications
- **Retrospective validation**: Known successful repurposing cases
- **Negative control validation**: Random compound-disease pairs

### **Cost Optimization**
- **Cache hit ratio**: > 80% for common queries
- **Compute efficiency**: GPU utilization > 70%
- **Storage tiering**: Hot/warm/cold data lifecycle management

---

## **Implementation Roadmap**

### **Phase 1 (Months 1-3)**
- Deploy core agents (Literature, Trials, Safety)
- Implement basic orchestration
- Establish audit trail foundation

### **Phase 2 (Months 4-6)**
- Add PK/PD and biomarker agents
- Deploy graph and vector databases
- Implement validation framework

### **Phase 3 (Months 7-12)**
- Full agent suite deployment
- Regulatory documentation package
- Enterprise scaling and optimization

### **Phase 4 (Ongoing)**
- Continuous improvement via reinforcement learning
- Expansion to new data sources
- Regulatory submission integration

This architecture balances innovation with compliance, providing a robust foundation for automated drug repurposing while meeting stringent pharmaceutical regulatory requirements. The modular design allows for incremental validation and deployment, critical for regulated environments.